By Carlos Nakens.
Spanish biomedical research has taken a bold step toward the future. At the University of La Rioja, three young scientists have recently defended their doctoral theses with disruptive approaches to detect and combat cancer from its earliest stages. Accompanied by experts in biomedicine, biochemistry, and emerging technologies, these researchers aim not only to improve existing treatments but to radically transform the way we understand and tackle this disease. Their advances, funded by national and European programs, could save millions of lives in the coming years.
Smart Nanosensors: Early Diagnosis with Millimetric Precision
The thesis proposes a revolution in routine medical analyses. Its proposal: highly sensitive nanosensors designed to detect tumor biomarkers in blood. These devices, based on gold nanoparticles and monoclonal antibodies, have demonstrated unprecedented ability to identify signals of lung and pancreatic cancer at asymptomatic stages.
“We want a blood test to be enough to anticipate the disease,” says Gutiérrez. Preliminary trials have reached an effectiveness of 93%, opening the door to a new standard in preventive medicine.
Personalized Vaccines Against Melanoma: When AI and the Immune System Join Forces
This thesis explores cutting-edge immunotherapy: personalized vaccines based on the unique neoantigens of each tumor. Using artificial intelligence algorithms, the team has developed a platform that identifies specific melanoma mutations and generates vaccine compounds capable of training the immune system to recognize and destroy tumor cells.
“No two cancers are alike, and neither should two treatments be,” affirms Sampedro. In vitro studies have revealed an immune activation of 87%, and preclinical trials are already being prepared.
Gene Therapy to Halt Metastasis: The New Battlefield
The third research project delves into one of cancer’s most feared frontiers: metastasis. Its work focuses on an experimental gene therapy that employs modified viral vectors to silence key genes involved in tumor spread. In breast cancer cell lines, the therapy has reduced cell migration by more than 70%.
“Our goal is not only to halt cancer but to genetically deactivate it,” explains Moreno. Although the results are still preliminary, the potential of this therapeutic pathway has sparked interest from international laboratories.
The three projects represent much more than academic advances: they are a real promise of change. Professor Álvaro Díaz, director of the Department of Biomedicine, highlights the importance of these investigations:
“We are training the next generation of scientific leaders. What is a thesis today will be a treatment tomorrow.”
Thus, the University of La Rioja is consolidating itself as a hub of biomedical innovation in Europe. Its researchers have shown that with vision, institutional support, and ethical commitment, science can illuminate the path toward more precise, humane, and effective medicine.
And as one of the doctoral candidates reminds us, “investing in science is not an expense: it is the greatest act of love toward the future.”
Add comment
Comments